21-hydroxylase deficiency differential diagnosis: Difference between revisions

Jump to navigation Jump to search
(/* 21-hydroxylase deficiency classic typ e must be differentiated from diseases that cause ambiguous genitalia:{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for dia...)
No edit summary
Line 10: Line 10:
21-hydroxylase deficiency classic form should be differentiated from other diseases that cause [[ambiguous genitalia]], and non-classic form should be differentiated from the diseases that cause female [[hirsutism]].
21-hydroxylase deficiency classic form should be differentiated from other diseases that cause [[ambiguous genitalia]], and non-classic form should be differentiated from the diseases that cause female [[hirsutism]].


=== 21-hydroxylase deficiency classic typ e must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> ===
'''21-hydroxylase deficiency classic type must be differentiated from diseases that cause [[ambiguous genitalia]]:'''<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref>
{| class="wikitable"
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name
Line 90: Line 90:
|}
|}


=== [[21-hydroxylase deficiency]] non-classic type must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref> ===
'''[[21-hydroxylase deficiency]] non-classic type must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:'''<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref>
{| class="wikitable"
{| class="wikitable"
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name
Line 97: Line 97:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
|-
|Non-classic type of [[21-hydroxylase deficiency]]
| align="center" style="background:#DCDCDC;" + |Non-classic type of [[21-hydroxylase deficiency]]
|Increased:
|Increased:
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
Line 108: Line 108:
* [[Virilization]] in females
* [[Virilization]] in females
|-
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="background:#DCDCDC;" + |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|Increased:
|Increased:
* DOC
* DOC
Line 122: Line 122:
* [[Virilization]]
* [[Virilization]]
|-
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="background:#DCDCDC;" + |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
|Increased:
* [[DHEA]]
* [[DHEA]]
Line 138: Line 138:
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.  
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.  
|-
|-
|[[Polycystic ovary syndrome ]]
| align="center" style="background:#DCDCDC;" + |[[Polycystic ovary syndrome ]]
|
|
* High [[DHEAS]] and [[androstenedione]] levels
* High [[DHEAS]] and [[androstenedione]] levels
Line 149: Line 149:
* No evidence another diagnosis  
* No evidence another diagnosis  
|-
|-
|[[Adrenal tumors]]
| align="center" style="background:#DCDCDC;" + |[[Adrenal tumors]]
|
|
* Variable levels depends on [[tumor]] type
* Variable levels depends on [[tumor]] type
Line 158: Line 158:
* Rapidly progressive symptoms
* Rapidly progressive symptoms
|-
|-
|Ovarian [[virilizing]] tumor
| align="center" style="background:#DCDCDC;" + |Ovarian [[virilizing]] tumor
|
|
* Variable levels depends on [[tumor]] type
* Variable levels depends on [[tumor]] type
Line 167: Line 167:
* Rapidly progressive symptoms
* Rapidly progressive symptoms
|-
|-
|[[Cushing's syndrome]]
| align="center" style="background:#DCDCDC;" + |[[Cushing's syndrome]]
|
|
* Increase [[cortisol]] & metabolites
* Increase [[cortisol]] & metabolites
Line 176: Line 176:
* [[Cushingoid appearance]]
* [[Cushingoid appearance]]
|-
|-
|[[Hyperprolactinemia]]
| align="center" style="background:#DCDCDC;" + |[[Hyperprolactinemia]]
|
|
* Normal levels of most of [[steroids]]
* Normal levels of most of [[steroids]]

Revision as of 21:39, 13 November 2017


Congenital adrenal hyperplasia main page

21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 21-Hydroxylase Deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency differential diagnosis

CDC on 21-hydroxylase deficiency differential diagnosis

21-hydroxylase deficiency differential diagnosis in the news

Blogs on 21-hydroxylase deficiency differential diagnosis

Directions to Hospitals Treating 21-Hydroxylase Deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Mehrian Jafarizade, M.D [2]

Overview

21-hydroxylase deficiency must be differentiated from 11-β hydroxylase deficiency, 17-α hydroxylase deficiency, androgen insensitivity syndrome, 3 beta-hydroxysteroid dehydrogenase deficiency, polycystic ovarian syndrome, hyperprolactinemia, cushing syndrome, and adrenal tumor.

Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases

21-hydroxylase deficiency classic form should be differentiated from other diseases that cause ambiguous genitalia, and non-classic form should be differentiated from the diseases that cause female hirsutism.

21-hydroxylase deficiency classic type must be differentiated from diseases that cause ambiguous genitalia:[1][2]

Disease name Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

21-hydroxylase deficiency non-classic type must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]

Disease name Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:
  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

References

  1. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  2. 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  3. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  4. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=